Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheimer’s and Parkinson’s Disease Models

•    Findings published in the peer-reviewed journal ACS Chemical Neuroscience demonstrated increased survival in preclinical model of Alzheimer’s disease after administration of clinical molecule ASN90, as well as significant motor impairment and astrogliosis effect in a Parkinson’s model

•    Unique functional benefits in gold-standard preclinical models of Alzheimer’s and Parkinson’s disease highlight the significant potential of O-GlcNAcase inhibitors for disease modification


Lausanne, SWITZERLAND and San Francisco, CA, USA, 1 April 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces the publication of peer-reviewed data in the journal ACS Chemical Neuroscience regarding ASN90, an O GlcNAcase (OGA) inhibitor, and one of its leading candidates in clinical development for treating neurodegenerative proteinopathies.

Read more…


By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...